BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 3927464)

  • 1. Host defenses in patients with cystic fibrosis: modulation by Pseudomonas aeruginosa.
    Speert DP
    Surv Synth Pathol Res; 1985; 4(1):14-33. PubMed ID: 3927464
    [No Abstract]   [Full Text] [Related]  

  • 2. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction.
    Pier GB
    J Infect Dis; 1985 Apr; 151(4):575-80. PubMed ID: 3919113
    [No Abstract]   [Full Text] [Related]  

  • 3. Interaction between Pseudomonas aeruginosa and host defenses in cystic fibrosis.
    Marshall BC; Carroll KC
    Semin Respir Infect; 1991 Mar; 6(1):11-8. PubMed ID: 1909452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific antibodies overcome the opsonin-receptor mismatch of cystic fibrosis in vitro: restoration of neutrophil-mediated phagocytosis and killing of Pseudomonas aeruginosa.
    McCormick LL; Karulin AY; Schreiber JR; Greenspan NS
    J Immunol; 1997 Apr; 158(7):3474-82. PubMed ID: 9120309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgG subclasses and chronic bacterial infection. Subclass antibodies and the clinical course of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Pressler T
    APMIS Suppl; 1996; 66():1-41. PubMed ID: 8972694
    [No Abstract]   [Full Text] [Related]  

  • 6. Pseudomonas aeruginosa Psl polysaccharide reduces neutrophil phagocytosis and the oxidative response by limiting complement-mediated opsonization.
    Mishra M; Byrd MS; Sergeant S; Azad AK; Parsek MR; McPhail L; Schlesinger LS; Wozniak DJ
    Cell Microbiol; 2012 Jan; 14(1):95-106. PubMed ID: 21951860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunoevasive activities of Pseudomonas aeruginosa. Relevance for cystic fibrosis.
    Buret A; Cripps AW
    Am Rev Respir Dis; 1993 Sep; 148(3):793-805. PubMed ID: 8368651
    [No Abstract]   [Full Text] [Related]  

  • 8. Interaction of pseudomonas exoproducts with phagocytic cells.
    Weber B; Nickol MM; Jagger KS; Saelinger CB
    Can J Microbiol; 1982 Jun; 28(6):679-85. PubMed ID: 6811122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides.
    Young LS
    J Infect Dis; 1972 Sep; 126(3):277-87. PubMed ID: 4626510
    [No Abstract]   [Full Text] [Related]  

  • 10. Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors.
    Young LS; Armstrong D
    J Infect Dis; 1972 Sep; 126(3):257-76. PubMed ID: 4626509
    [No Abstract]   [Full Text] [Related]  

  • 11. Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection.
    Tosi MF; Zakem-Cloud H; Demko CA; Schreiber JR; Stern RC; Konstan MW; Berger M
    J Infect Dis; 1995 Aug; 172(2):453-61. PubMed ID: 7622889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay.
    Klinger JD; Straus DC; Hilton CB; Bass JA
    J Infect Dis; 1978 Jul; 138(1):49-8. PubMed ID: 98596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic aspects of cystic fibrosis.
    Döring G; Albus A; Høiby N
    Chest; 1988 Aug; 94(2 Suppl):109S-115S. PubMed ID: 3135159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudomonas aeruginosa infection in cystic fibrosis. Distribution of B and T lymphocytes in relation to the humoral immune response.
    Hoiby N; Mathiesen L
    Acta Pathol Microbiol Scand B Microbiol Immunol; 1974 Aug; 82(4):559-66. PubMed ID: 4213329
    [No Abstract]   [Full Text] [Related]  

  • 15. Immuno-modulatory functions of the type-3 secretion system and impacts on the pulmonary host defense: A role for ExoS of Pseudomonas aeruginosa in cystic fibrosis.
    Belmadi N; Wu Y; Touqui L
    Toxicon; 2018 Mar; 143():68-73. PubMed ID: 29339019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic aspects of surface infections in the lung.
    Piedra P; Ogra PL
    J Pediatr; 1986 May; 108(5 Pt 2):817-23. PubMed ID: 3084749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay.
    Fick RB; Naegel GP; Matthay RA; Reynolds HY
    J Clin Invest; 1981 Oct; 68(4):899-914. PubMed ID: 6793632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of antibody in infections due to Pseudomonas aeruginosa.
    Young LS
    J Infect Dis; 1974 Nov; 130 Suppl(0):S111-8. PubMed ID: 4213568
    [No Abstract]   [Full Text] [Related]  

  • 19. Nonopsonic phagocytosis of strains of Pseudomonas aeruginosa from cystic fibrosis patients.
    Speert DP; Eftekhar F; Puterman ML
    Infect Immun; 1984 Mar; 43(3):1006-11. PubMed ID: 6421734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic mechanisms of chronic Pseudomonas aeruginosa infections in cystic fibrosis patients.
    Høiby N; Döring G; Schiøtz PO
    Antibiot Chemother (1971); 1987; 39():60-76. PubMed ID: 3118792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.